PDCD1 and Miyoshi myopathy: More recently, it has been reported across a series of predominantly retrospective studies that the ORR achieved with anti‐PD‐1 was 14.0–16.6% and the median overall survival (OS) was 18.2–25.8 months in AM patients, and 0–23.2% and 11.5–20.2 months for MM patients, respectively.15, 16, 17, 18, 19, 20